BioCryst Pharmaceuticals, Inc.

NasdaqGS BCRX

BioCryst Pharmaceuticals, Inc. Share Price on January 14, 2025: USD 7.23

BioCryst Pharmaceuticals, Inc. Share Price is USD 7.23 on January 14, 2025, a 18.72% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.
  • BioCryst Pharmaceuticals, Inc. 52-week high Share Price is USD 8.69 on August 30, 2024, which is 20.19% above the current Share Price.
  • BioCryst Pharmaceuticals, Inc. 52-week low Share Price is USD 4.13 on April 30, 2024, which is -42.88% below the current Share Price.
  • BioCryst Pharmaceuticals, Inc. average Share Price for the last 52 weeks is USD 6.64.
Key data
Date Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B)
Market news
Loading...
NasdaqGS: BCRX

BioCryst Pharmaceuticals, Inc.

CEO Mr. Jon P. Stonehouse
IPO Date March 4, 1994
Location United States
Headquarters 4505 Emperor Boulevard
Employees 536
Sector Health Care
Industries
Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Similar companies

BIVI

BioVie Inc.

USD 2.01

-4.29%

VKTX

Viking Therapeutics, Inc.

USD 33.93

-12.73%

ATRA

Atara Biotherapeutics, Inc.

USD 12.31

-23.96%

MDGL

Madrigal Pharmaceuticals, Inc.

USD 274.12

-9.74%

AVXL

Anavex Life Sciences Corp.

USD 10.47

-0.76%

IMUX

Immunic, Inc.

USD 1.00

-6.54%

INMB

INmune Bio, Inc.

USD 5.96

-8.87%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

APLS

Apellis Pharmaceuticals, Inc.

USD 27.69

-3.15%

AXSM

Axsome Therapeutics, Inc.

USD 84.60

-5.23%

TGTX

TG Therapeutics, Inc.

USD 29.74

7.48%

SAVA

Cassava Sciences, Inc.

USD 2.61

-4.40%

BPMC

Blueprint Medicines Corporation

USD 102.56

-0.77%

KZR

Kezar Life Sciences, Inc.

USD 6.21

-1.43%

PDSB

PDS Biotechnology Corporation

USD 1.39

-2.11%

StockViz Staff

January 15, 2025

Any question? Send us an email